Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of sodium zirconium cyclosilicate for chronic kidney disease progression in patients with hyperkalaemia risk
2021-001911-96Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) and hyperkalemia comparing Sodium zirconium cyclosilicate plus ACEi/ARB with Placebo plus ACEi/ARB (2 arms). Primary endpoints: Co-primary endpoint: eGFR decline over time and Co-primary endpoint: composite kidney failure outcome. Started Oct 2021; status: terminated.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
chronic kidney disease (CKD)hyperkalemia
Beyond the preview
Go deeper on 2021-001911-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001911-96.